Remedeine

Quick links to important sections

Remedeine

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Remedeine

Property Description
Active Ingredients Acetaminophen (Paracetamol) and Dihydrocodeine
Form Tablet or Capsule (Oral Solid)
Pharmacological Class Combination Analgesic, Opioid Analgesic
General Purpose Relief of moderate to severe pain
Regulatory Status Prescription-only medicine

What Type of Medicine is Remedeine and What Does it Contain?

Remedeine is a potent combination analgesic, classified as a Prescription-only medicine, known primarily for its dual active ingredients: Acetaminophen and Dihydrocodeine. This specific formulation is distinguished by combining a central-acting opioid analgesic (Dihydrocodeine) with a non-opioid pain reliever (Acetaminophen), a strategy favored for its efficacy in difficult-to-manage pain. Both active compounds are the result of synthetic pharmaceutical processes. Due to its composition, Remedeine belongs to the broader Opioid analgesic drug group. It is supplied as an oral formulation—typically a tablet or capsule—for systemic administration. The Acetaminophen component, an Anilide analgesic, works to support and enhance the pain-relieving effects of the opioid component.

What is the General Purpose of Remedeine's Dual Formulation?

The general therapeutic purpose of this dual formulation is to achieve synergistic analgesia, where the combined effect of the two ingredients is significantly greater than their isolated actions. This robust pharmacological approach is widely clinically recognized for providing potent analgesia suitable for managing pain generally characterized as moderate to severe. There is an established use of dihydrocodeine combination products in relieving chronic non-malignant pain. This combination is typically reserved for situations where the patient's discomfort is not adequately controlled by over-the-counter or single-agent therapies. The formulation works by having the Dihydrocodeine component act centrally on pain receptors, while the Acetaminophen component works via central pathways and helps reduce fever.

Regulatory References

  1. NIH/NLM DailyMed Drug Label

What side effects are possible with Remedeine?

Possible side effects and safety information

The safety characteristics of this combination analgesic, containing Acetaminophen and Dihydrocodeine, are defined by the risks associated with both active components, as formally documented in regulatory prescribing information.

Official Adverse Reaction Classifications

Adverse reactions are grouped by the physiological system affected and classified by occurrence frequency:

  • Common Reactions: These frequently observed effects primarily involve the Nervous System (e.g., drowsiness, dizziness, sedation, headache) and the Gastrointestinal System (e.g., nausea, vomiting, constipation). Constipation is a commonly documented adverse reaction associated with the opioid component.
  • Rare Reactions: The label notes severe and potentially life-threatening Skin and Subcutaneous Tissue Disorders, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are classified as very rare.

Documented Serious Adverse Risks

Regulatory documents emphasize specific, serious risks. The most critical acute risk is Life-Threatening Respiratory Depression from the opioid component, which is noted to be greatest during the initiation of therapy or following a dosage increase. The Acetaminophen component carries the serious risk of Acute Liver Failure (hepatotoxicity), especially when the maximum recommended daily limit is exceeded. Chronic exposure is associated with risks of Physical Dependence and Addiction.

Population-Specific Safety Statements

Official labeling defines specific constraints for certain groups. The medicine is contraindicated in children younger than 12 years of age and is not recommended for use in breastfeeding mothers due to the risk of serious adverse effects on the infant. Caution is also advised when administering the medicine to older or debilitated patients, as they may be more susceptible to adverse effects like respiratory depression.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation describes the overdose profile for Remedeine based on the toxicities of its two components: Acetaminophen and Dihydrocodeine.

Documented Overdose Manifestations

Symptoms may initially include nausea, vomiting, or abdominal pain due to the Acetaminophen component. These can be followed by signs of severe Central Nervous System (CNS) depression from Dihydrocodeine, such as extreme drowsiness, stupor, loss of consciousness (coma), or constricted pupils (miosis).

Severe and Life-Threatening Outcomes

Overdose carries a risk of potentially fatal outcomes, including dose-dependent hepatic necrosis (acute liver failure) and severe, life-threatening respiratory depression (slow or stopped breathing). Cardiovascular collapse and renal tubular necrosis are also documented complications. The risk of toxic reactions may be greater in individuals with existing liver or kidney impairment.

Mandated Emergency Actions

Immediate medical attention is required for any suspected overdose, even if symptoms are not immediately apparent. Because severe hepatic toxicity can be delayed, regulatory authorities mandate that emergency services or a Poison Control Center be contacted right away. Two specific antidotes are used in management: N-acetylcysteine for Acetaminophen toxicity and Naloxone to reverse the opioid effects. Treatment involves symptomatic and supportive care, including continuous monitoring of vital signs and laboratory parameters, often requiring hospital admission for observation and intervention.

Therapeutic Uses of Remedeine

What Remedeine Treats: Main Uses and Benefits

Remedeine is a combination analgesic used in situations involving certain distressing symptoms, specifically applied across domains where additional symptomatic support is needed. The medication is applied in therapeutic domains where strong symptomatic management is considered appropriate, typically for discomfort that is either severe or refractory to standard treatments.

Acute and Episodic Symptom Management

The medication is commonly used across conditions presenting with acute episodes. It is applied in addressing symptoms that create noticeable physiological strain and discomfort, relevant for managing symptom clusters that may become intense or disruptive. The primary indications include short-term support for postoperative pain, discomfort following physical trauma, and acute musculoskeletal flare-ups.

Applied during phases of increased distress, this use assists with maintaining functional stability and contributes to easing the overall symptom load during symptomatic phases. Additionally, it is relevant for easing symptoms related to systemic imbalance, such as fever.


Quick Fact: Relief for Severe or Refractory Discomfort.

Regulatory References

  1. NIH DailyMed Drug Information

Eligibility and Restrictions for Use

Eligibility for Remedeine Use

Remedeine (a combination product similar to Co-dydramol, containing an opioid component and paracetamol) is subject to strict eligibility rules as defined by regulatory bodies to prevent serious harm, particularly respiratory depression.

Group Eligibility Status (Official Regulatory Statement)
Children under 12 years Contraindicated (Must not be used).
Adolescents (12–18) Contraindicated after tonsillectomy/adenoidectomy. Not recommended if breathing is compromised.
Adults (All ages) Contraindicated in cases of significant respiratory depression, acute or severe asthma in an unmonitored setting, and gastrointestinal obstruction (e.g., paralytic ileus).
Genetic Status Contraindicated in individuals known to be ultra-rapid metabolizers of the opioid component.
Pregnancy Avoid use during the first trimester. Use in late pregnancy may cause neonatal withdrawal.
Lactation Not recommended for breastfeeding mothers, as the active substance passes into breast milk and may cause serious respiratory issues in the infant.

Use is also cautioned and may require a reduced dosage in patients with renal (kidney) or hepatic (liver) impairment and certain chronic conditions like hypothyroidism.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Remedeine, containing dihydrocodeine and paracetamol (acetaminophen), has established interactions documented in authoritative regulatory labeling. This information identifies specific drug combinations and substances that affect safety or drug exposure.

Documented Interaction Categories

Category Description and Examples
CNS Depressants Co-administration with other Central Nervous System depressants (e.g., sedatives, hypnotics, general anesthetics) is officially warned against due to the risk of additive effects.
Metabolic Inhibitors Substances that inhibit the CYP2D6 enzyme (e.g., certain antidepressants) may reduce the conversion of dihydrocodeine into its active metabolite, potentially altering the drug's intended action.
Oral Anticoagulants Chronic, high-dose use of the paracetamol component may enhance the effects of coumarin anticoagulants (e.g., Warfarin), requiring careful monitoring.
Absorption Modifiers Agents that alter gastric emptying (e.g., Metoclopramide, Domperidone) can increase the rate of paracetamol absorption. Conversely, Cholestyramine can reduce paracetamol absorption, necessitating dose separation.

Substance-Related Warnings

Official regulatory information emphasizes that the concurrent use of alcohol is linked to an enhanced risk of both central nervous system depression and potential paracetamol-related liver toxicity. Additionally, combination with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated.

Mechanism of Action

Remedeine acts primarily as a regulator of bone resorption through its interaction with the calcitonin signaling pathway. The compound functions as a partial agonist at the calcitonin receptor, leading to a cAMP-mediated reduction in osteoclast differentiation and activity. This results in a conformational change of the receptor protein.

The drug selectively targets the cAMP pathway in cells expressing the calcitonin receptor and inhibits the binding affinity of parathyroid hormone to its receptor. This mechanism modulates the activity of RANKL and osteoprotegerin signaling pathways, which in turn leads to a net decrease in TRAP expression by osteoclast precursors. The net effect is a reduction in the rate of bone mineral release.

Dosage and Administration Information

The use of Remedeine, a combination analgesic, follows established administration protocols. Administration is strictly confined to the oral route, typically via solid forms such as tablets or capsules. The standard unit dose for adults and adolescents aged 16 and over is one or two tablets, taken as required for symptomatic management.

The medication is taken according to a defined frequency pattern of every four to six hours, with a mandatory minimum interval of four hours required between subsequent doses. A critical constraint is the total dose ceiling; intake must not exceed eight tablets within any 24-hour period. This limit aligns with the maximum permissible intake of the acetaminophen component, which is capped at 4,000 mg per day.

From a procedural standpoint, tablets should be swallowed whole with water, preferably during or after meals, and must not be crushed. Furthermore, the use is designated as short-term only, with use for more than three days generally requiring formal clinical review. Specific adjustments are required for certain populations: the dosage must be reduced in older adults and individuals with hepatic or renal impairment, and the product is not recommended for children under 12 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies for Remedeine


Evidence for Use in Moderate to Severe Acute Pain

Research examined Remedeine as an option for adults facing acute, severe discomfort, such as following surgical procedures or physical trauma. Studies explored short-term symptom changes and monitored patient-reported outcomes related to physical discomfort, pain intensity, and overall symptom load. Research documentation described patterns observed in trials used in the context of short-term acute symptom management. The full long-term context of these observed patterns remains uncertain, as follow-up durations are typically limited in acute trials.


Evidence for Use in Chronic Non-Malignant Pain

Remedeine was evaluated in adult populations managing chronic non-malignant pain. Research utilized Systematic Reviews, including authoritative analyses, which synthesize data from underlying Randomized Controlled Trials and observational studies. These studies explored how symptoms change over time and monitored outcomes reflecting daily functioning. An authoritative review examined patterns observed for this formulation. However, the uniformity of reported functional outcomes and data across diverse chronic pain causes remain areas for further investigation.


Long-Term Observation and Follow-up Data

Studies conducted during periods of increased symptom activity typically had limited follow-up durations, meaning long-term outcomes in acute settings are not fully established. For chronic conditions, evidence contributes to understanding the long-term context, but effects on factors beyond symptom scores are not well characterized, and certainty remains low regarding sustained, comprehensive functional outcomes.


Studies in Specific Patient Populations

Remedeine research primarily focused on general adult populations. Data for certain groups, such as older adults, patients with pre-existing conditions (comorbidities), or pregnant populations, remain limited or unavailable in the core evidence. Evidence for use in the pediatric population remains limited.


Research Gaps and Remaining Uncertainties

Key uncertainties include the limited follow-up durations in acute trials and the variability of evidence quality across studies for chronic conditions. Comparative evidence is often lacking for certain standard outcome measurements. The evidence describes what is known and what is still uncertain, indicating that data for certain patient subgroups remain insufficient.

Key Studies & References Drug Information for Dihydrocodeine and Acetaminophen Combination Products (NIH DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Remedeine (FAQ)


Q: Do the side effects of Remedeine vary widely between individuals?

A: Official documents indicate that the way this medicine affects a person can vary, largely due to individual genetic differences in how the body processes the dihydrocodeine component. This variability is one reason why dosage adjustments are officially indicated or may be required for people with pre-existing conditions like liver or kidney impairment.


Q: How long should I expect initial side effects from Remedeine to last?

A: Initial side effects often experienced by new users, such as drowsiness or feeling sick, typically wear off within a few days as the body adjusts to the medicine. Official guidance notes that if these initial effects persist or worsen, it is important to consult a healthcare professional.


Q: Can Remedeine be taken if I am already taking common over-the-counter pain relievers?

A: Because Remedeine contains acetaminophen (paracetamol), official warnings state that other products containing this ingredient should not be taken. Combining them risks exceeding the maximum daily dose, which is associated with a serious risk of liver damage.


Q: Are there any specific herbal supplements that are known to interact with Remedeine?

A: Official labeling describes the importance of informing a health professional about all substances being taken, including any herbal products and dietary supplements. This practice ensures that potential interactions with the medicine’s components can be reviewed.


Q: How quickly does Remedeine typically start to produce its intended effect?

A: According to official patient information, the standard tablet formulation typically begins to produce its intended pain-relieving effect between one and a half and two hours after ingestion.


Q: Is Remedeine available in different forms or strengths?

A: Official product information indicates that Remedeine is available in multiple tablet or capsule strengths. While the amount of paracetamol (acetaminophen) is generally standard in these formulations, the quantity of the dihydrocodeine component varies between strengths.


Q: How is Remedeine different from other similar medicines used for the same issue?

A: Remedeine is officially defined as a combination analgesic because it contains two distinct active ingredients: the opioid dihydrocodeine and the non-opioid paracetamol. This dual formulation is intended to provide a synergistic effect for the management of moderate to severe pain.


Q: Why is Remedeine sometimes confused with other drugs in the same class?

A: This medicine is the brand name for the generic combination product known in certain regions as Co-dydramol. This common name structure can lead to confusion with other similarly formulated combination products that pair an opioid analgesic with paracetamol.


Q: Is there an official system for tracking adverse effects of Remedeine?

A: Regulatory bodies mandate a system for reporting and tracking suspected Adverse Drug Reactions (ADRs). Official guidance includes information on how individuals can report any side effects they experience to their national regulatory authority or their prescribing healthcare professional.


Q: Does Remedeine have any known effects on driving ability or operating machinery?

A: Official warnings describe restrictions on driving or operating machinery due to the risk of side effects like drowsiness and dizziness. This caution remains in place until the individual is certain that the medicine does not impair their ability to perform these tasks safely.


Q: Can Remedeine affect routine lab test results?

A: Official documents note that the paracetamol (acetaminophen) component of Remedeine may interfere with some laboratory tests. This interference is specific to tests that are used to measure levels of uric acid and blood glucose.


Q: What information is included in the official Patient Information Leaflet (PIL) for Remedeine?

A: The official Patient Information Leaflet (PIL) provides essential non-clinical details on the safe use of the medicine. This includes information on how and when to take it, a summary of possible side effects, warnings about interactions, and specific instructions for various patient groups.


Q: Does Remedeine contain common ingredients like lactose or gluten?

A: The specific inactive ingredients, known as excipients, that are contained within the tablets or capsules are listed in the official Summary of Product Characteristics (SmPC). Official documentation states that this listing should be reviewed by individuals with known sensitivities.


Q: What are the official guidelines for dealing with potential drug interactions?

A: Official guidance emphasizes the importance of consulting a healthcare professional if a patient suspects a drug interaction or is considering taking any new medicine or supplement. This allows for a timely review of the person's medication regimen and guidance on how to proceed.


Q: Is there a risk that Remedeine could become less effective over time?

A: Studies and official warnings indicate that with prolonged or continuous use, the body may develop a phenomenon known as tolerance to the dihydrocodeine component. This means that over time, the medicine may become less effective at the original dose, and this outcome indicates the need for professional review.


Q: Where can I find the most authoritative and up-to-date information on Remedeine?

A: The most current and authoritative regulatory information is made public by national authorities like the FDA, EMA, or MHRA/GOV.UK. This documentation is often published as the Summary of Product Characteristics (SmPC) or the official Patient Leaflet.


Q: Is Remedeine available without a prescription in some countries?

A: The regulatory status of Remedeine can depend on its strength and the specific jurisdiction. While higher strengths are typically classified as prescription-only, the lowest strength may be available for purchase directly from a pharmacy without a doctor's prescription in some regions.


Q: Are there any known side effects associated with stopping Remedeine use?

A: Official warnings note that after long-term use, abruptly stopping the medicine can lead to physical and psychological withdrawal effects. Official guidance describes the requirement for the dose to be gradually reduced under the supervision of a health professional.


Q: Can Remedeine interact with common foods or juices, like grapefruit?

A: Official warnings describe restrictions on consuming grapefruit or grapefruit juice while using this medicine. This is because these products may interfere with the metabolism of the drug, which can potentially increase the risk of more serious side effects.


Q: Is it true that Remedeine is primarily broken down by the liver?

A: Yes. Regulatory warnings confirm that the active components are primarily metabolized (broken down) in the liver using specific enzymes. This reliance on the liver is the basis for the strong official warnings regarding the serious risk of liver damage if the maximum daily dose is exceeded.


Q: What does the term 'contraindication' officially mean for Remedeine users?

A: A contraindication is a mandatory official statement that the medicine is excluded from use in a specific circumstance, condition, or patient group. It indicates that the potential for serious harm or a life-threatening reaction is too high to justify its use.


Q: Is Remedeine considered a controlled substance in certain jurisdictions?

A: Due to the presence of dihydrocodeine, an opioid component, Remedeine is typically classified as a Controlled Drug. This status subjects the medicine to strict legal controls concerning its prescribing, supply, storage, and disposal across various jurisdictions.


Q: Does Remedeine require any special medical monitoring (like blood tests) during use?

A: Monitoring may be required, particularly for people taking the medicine long-term or those using it with other medicines like oral anticoagulants (Warfarin). Official information indicates that regular tests, such as blood tests, may be advised in these situations.

How should Remedeine be stored and disposed of?

Remedeine (Co-dydramol) must be stored and disposed of according to official regulatory requirements, primarily due to its opioid component, dihydrocodeine.

Storage Requirements

Remedeine tablets should be stored at room temperature, which is officially defined as below 25 C. The product must be kept in the original container and sealed tightly closed to protect the contents from moisture. To prevent loss of stability, the medicine must not be refrigerated or frozen. Due to the presence of an opioid, it is mandatory to store Remedeine strictly out of the sight and reach of children.

Official Disposal Rules

Unused or expired Remedeine must be handled as a controlled substance. The preferred method of disposal is to take the medicine to an authorized drug take-back program or collection site. If a take-back program is unavailable, consult the patient information leaflet or national guidance, as certain opioids are recommended for immediate flushing. Medicines should not be disposed of via household trash or wastewater unless specific official steps are followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Remedeine found in:

A-Z Index: